Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 103.57% and 4.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is Omnicell (OMCL) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
Encompass Health's (EHC) Q1 Earnings Beat, '23 EPS View Up
by Zacks Equity Research
Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 457.14% and 4.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
by Zacks Equity Research
Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.
NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 36.80% and 72.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its planned geographic expansion.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.
Omnicell (OMCL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 266.67% and 3.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Omnicell, Carnival, Atlantica Sustainable Infrastructure and TFS Financial
by Zacks Equity Research
Omnicell, Carnival, Atlantica Sustainable Infrastructure and TFS Financial have been highlighted in this Screen of The Week article.
Don't Risk Your Hard-Earned Money for These 4 Toxic Stocks
by Rimmi Singhi
Identifying toxic stocks and offloading them at the right time can help you avoid huge losses. OMCL, CCL, AY and TFSL are a few such toxic stocks that you should dump right away.
Zacks.com featured highlights Bally's, Omnicell, Atlantica Sustainable Infrastructure and TFS Financial
by Zacks Equity Research
Bally's, Omnicell, Atlantica Sustainable Infrastructure and TFS Financial have been highlighted in this Screen of The Week article.
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Toxic Stocks That May Not Let You Prosper
by Rimmi Singhi
If you own toxic stocks for long, you are likely to see a big loss in your wealth. Stay away from toxic stocks like BALY, OMCL, AY and TFSL.
Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio
by Rimmi Singhi
Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.
Do Options Traders Know Something About Omnicell (OMCL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Omnicell (OMCL) stock based on the movements in the options market lately.